Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge is advising Xspray Pharma in connection with its rights issue of units
Mandate

Vinge is advising Xspray Pharma in connection with its rights issue of units

May 04, 2023 Capital Markets and Public M&A

Through the rights issue of units, Xspray is expected to receive approximately SEK 300 million, with two warrant series approximately amounting together up to an additional SEK 300 million upon full exercise.

Xspray Pharma AB (publ) is a pharmaceutical company that specializes in using its patented HyNap-technology to develop improved versions of existing protein kinase inhibitors (PKIs) for cancer treatment. The company's goal is to become a leader in the development of improved PKIs for cancer treatment. Xspray’s shares are listed on Nasdaq Stockholm.

Vinge’s team primarily consisted of Dain Hård Nevonen, Linnéa Sellström and Adrian Filipovic.

 

Related

Vinge advises on the sale of Compab to Tången

 Vinge has advised the owners of Compab Energiteknik in connection with the sale of 80 per cent of the shares to Tången Industrikapital. Compab, which has a turnover of approximately SEK 100 million, sells, installs and services, amongst other things, steam and hot-water boilers as well as burners for the industrial sector.
October 26, 2026

Vinge advises Capio on the acquisition of Rehabhotellet Sthlm AB

 Rehabhotellet i Sthlm AB provides advanced home healthcare and specialized inpatient palliative care within the Stockholm Region.
October 26, 2026

Vinge advises Ikano Bank on acquisition of loan portfolio from Entercard

 Vinge has advised Ikano Bank AB (publ) on the acquisition of a portfolio of performing consumer loans from Entercard Group AB. As at 30 September 2026, the contractual amount of the loans totalled approximately SEK 7 billion.
October 26, 2026